

Date: 5<sup>th</sup> February, 2024

To,  
The Manager,  
Department of Corporate Services,  
BSE Limited  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400 001  
Scrip Code: 533573

To,  
The Manager,  
Listing Department,  
National Stock Exchange of India Ltd.  
'Exchange Plaza', Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
NSE Symbol: APLLT D

Dear Sir / Madam,

**Sub: Outcome of Board Meeting**

With reference to the captioned Subject, the exchange is hereby informed that the Board of Directors of Alembic Pharmaceuticals Limited at its meeting held today has inter-alia:

- 1) Approved the Unaudited Financial Results for the quarter and nine months period ended 31<sup>st</sup> December, 2023.

We enclose herewith the following:

- a) Consolidated Unaudited Financial Results for the quarter and nine months period ended 31<sup>st</sup> December, 2023.
  - b) Standalone Unaudited Financial Results for the quarter and nine months period ended 31<sup>st</sup> December, 2023.
  - c) Limited Review Report by Statutory Auditors on the Consolidated and Standalone Unaudited Financial Results.
- 2) Designated Mr. Manuj Desai, Head – IT as Senior Management Personnel of the Company w.e.f. 6<sup>th</sup> February, 2024.

The details as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 is attached herewith as "Annexure-I".



**ALEMBIC PHARMACEUTICALS LIMITED**

The time of commencement of the Board Meeting was 11:45 a.m. and the time of conclusion was 2:00 p.m.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,

**For Alembic Pharmaceuticals Limited**



**Manisha Saraf**  
Company Secretary



Encl.: A/a.

**ALEMBIC PHARMACEUTICALS LIMITED**

Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") read with SEBI Circular SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13<sup>th</sup> July, 2023:

Sr. No.	Particulars	Details of Change - Mr. Manuj Desai
1.	Reason for change reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Designated as Senior Management Personnel
2	Date of appointment/cessation (as applicable) & term of appointment	6 <sup>th</sup> February, 2024  Term of Appointment: Full-time employment
3	Brief profile (in case of appointment)	<p>Mr. Manuj Desai has done his Bachelor of Engineering (B.E.) (Hon.) in Computer Science &amp; Technology from University of Mumbai and Masters Certificate in Project Management from George Washington University, Washington D.C., USA. He holds an impressive array of certifications including TOGAF 9, MEGA Certified Enterprise Architect, Certified Scrum Master, Certified ISO 9001 / SOX Auditor, Certified Software Configuration and Certified SQL / Java Developer Professional.</p> <p>Mr. Manuj Desai is a seasoned expert with extensive experience spanning over 24+ years in the Technology Industry.</p> <p>He was associated with Sterlite Technologies Limited, Upgrad Education Private Limited, American International Group, Inc. India, Paypal India Private Limited, US Department of Agriculture, MO, USA (@N-link Corp / SAIC), etc.</p>
4	Disclosure of relationships between directors	Not Applicable.

**ALEMBIC PHARMACEUTICALS LIMITED**

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003, INDIA • TEL : +91-265-2289550 • FAX : +91-265-2282937

Website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in

CIN: L24236GJ2010PLC081123